RxDoctor Payments Data

Steven Santiago

Adult Medicine · Miami, FLNPI 1316080682

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $197,025 of the $289,608 with a category attached, or 68.0%. 15 manufacturers reported payments, led by Gilead at 46.4% of the total. Reporting peaked in 2019 at $122,176 and has fallen 85.3% since, to $17,953 in 2025. Among adult medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$289,608in general payments, 2019–2025

Across 748 payments — averaging $387.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$134K
  • Janssen Scientific Affairs, LLC$118K
  • Viiv Healthcare Company$30K
  • Theratechnologies Inc.$3K
  • Janssen Products, LP$3K
  • Johnson & Johnson$846
  • plus $926 from 9 others

What the payments were for

  • Consulting fees$35,53012%
  • Speaking & faculty fees$197,02568%
  • Travel & lodging$42,18515%
  • Food & beverage$14,8175%
  • Education$500%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$289,608 in reported general payments places this provider in the 95th percentile of 195 adult medicine providers in Florida.

See all adult medicine providers in Florida

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala129$499,433
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf25$126,417
CabenuvaCabotegravir/Rilpivirine19$117,523
DovatoDolutegravir Sodium/Lamivudine32$98,191
JulucaDolutegravir/Rilpivirine11$44,047
TivicayDolutegravir Sodium18$43,904
MytesiCrofelemer13$30,758
OzempicSemaglutide16$16,637
ValacyclovirValacyclovir Hcl24$958
Rosuvastatin Calcium42$882
Pregabalin14$321
Gabapentin20$253
Zolpidem Tartrate21$156
Losartan Potassium13$156
Ketoconazole12$128

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$134,236$499,433129 claims
Viiv Healthcare CompanyCabenuva, Dovato, Juluca, Tivicay$30,437$303,66680 claims
Janssen Products, LPSymtuza$2,640$126,41725 claims
Napo Pharmaceuticals IncMytesi$15$30,75813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 195 adult medicine providers in Florida.

Other adult medicine in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →